In silico drug repurposing in COVID-19: A network-based analysis.
Biomed Pharmacother
; 142: 111954, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1330660
ABSTRACT
The SARS-CoV-2 pandemic is a worldwide public health emergency. Despite the beginning of a vaccination campaign, the search for new drugs to appropriately treat COVID-19 patients remains a priority. Drug repurposing represents a faster and cheaper method than de novo drug discovery. In this study, we examined three different network-based approaches to identify potentially repurposable drugs to treat COVID-19. We analyzed transcriptomic data from whole blood cells of patients with COVID-19 and 21 other related conditions, as compared with those of healthy subjects. In addition to conventionally used drugs (e.g., anticoagulants, antihistaminics, anti-TNFα antibodies, corticosteroids), unconventional candidate compounds, such as SCN5A inhibitors and drugs active in the central nervous system, were identified. Clinical judgment and validation through clinical trials are always mandatory before use of the identified drugs in a clinical setting.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Simulación por Computador
/
Reposicionamiento de Medicamentos
/
COVID-19
/
Tratamiento Farmacológico de COVID-19
Tipo de estudio:
Estudio pronóstico
Tópicos:
Vacunas
Límite:
Humanos
Idioma:
Inglés
Revista:
Biomed Pharmacother
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
J.biopha.2021.111954
Similares
MEDLINE
...
LILACS
LIS